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Chronic obstructive pulmonary disease (COPD) symptoms in the morning, including dyspnea and sputum
production, affect patients’ quality of life and limit their ability to carry out even simple morning activities. It is now
emerging that these symptoms are associated with increased risk of exacerbations and work absenteeism,
suggesting that they have a more profound impact on patients than previously thought. The development of
validated patient-reported outcome (PRO) questionnaires to capture patients’ experience of COPD symptoms in the
morning is, therefore, vital for establishing effective and comprehensive management strategies. Although it is well
established that long-acting bronchodilators are effective in improving COPD symptoms, the limited available data
on their impact on morning symptoms and activities have been obtained with non-validated PRO questionnaires.
In this review, we discuss the impact of COPD symptoms in the morning and available tools used to evaluate them,
and highlight specific gaps that need to be addressed to develop standardized instruments able to meet regulatory
requirement. We also present available evidence on the effect of pharmacological therapies on morning symptoms.
Keywords: Morning symptoms, Onset of action, Once-daily, Long -acting muscarinic antagonists,
Long-acting β2 agonistsIntroduction
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive disease associated with substantial morbidity and
mortality [1]. It represents a significant economic burden
in terms of direct healthcare costs and indirect costs, such
as loss of productivity and premature death [2].
Characteristic symptoms of COPD, including progres-
sive dyspnea, cough and sputum production, have a con-
siderable impact on patients’ lives, in particular on those
of patients with severe COPD [3]. Breathlessness, which
is a consequence of the characteristic lung hyperinflation
seen in COPD [4], is one of the most frequently reported
symptoms [3] and significantly limits exercise capacity
[5]. Several studies have described fluctuations of COPD
symptoms over the day, with morning considered the
time when symptoms are more severe [3,6-9]. Morning
symptoms restrict patients’ ability to carry out morning
routines and everyday activities [3,6-8] and might be as-
sociated with increased frequency of exacerbations [8].* Correspondence: nicolas.roche@cch.aphp.fr
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reproduction in any medium, provided the orTwo of the main aims of pharmacological manage-
ment of COPD are relief of symptoms and increase of
patients’ ability to exercise and carry out daily activities,
with the final goal of improving important outcomes in
COPD, such as health-related quality of life [1]. Long-
acting inhaled bronchodilators are the recommended
first-line maintenance therapy for COPD; treatment
options include long-acting muscarinic antagonists
(LAMAs) and long-acting β2-agonists (LABAs) [1].
According to the new Global Initiative for Chronic
Obstructive Lung Disease (GOLD) strategy document,
inhaled corticosteroids (ICS) are only recommended in
combination with LABAs, in patients with severe and
very severe airflow limitation (GOLD severity of airflow
obstruction grades 3 and 4) and/or frequent exacerba-
tions (group C and D in the 2011 update). Other guide-
lines and marketing authorizations restrict the use of
these combinations to patients who exhibit both these
features and are not controlled by long-acting broncho-
dilators [1]. Although it has been well established that
long-acting bronchodilators are effective in improving
COPD symptoms, patients’ health status and ability to ex-
ercise [1], data on the specific impact of pharmacologicalLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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limited.
This review will highlight the impact of COPD symp-
toms in the morning and provide an overview of tools
used to evaluate them. Available evidence on the effect
of pharmacological therapies on morning symptoms will
also be presented.Impact of symptoms in the morning on patients with
COPD
Circadian variation in lung function has been described
in patients with stable COPD, including variation in in-
spiratory capacity (IC) [10], forced expiratory volume in
1 second (FEV1) [10,11], forced vital capacity [10,11],
and peak inspiratory flow [12]. Cholinergic tone also has
a normal circadian rhythm with higher levels during the
sleeping hours, which can lead to airflow limitation in
patients with COPD and contribute to the variability of
symptoms [11]. An internet survey conducted in 803
patients with COPD revealed that, from a patient’s per-
spective, morning was the worst time for COPD symp-
toms, particularly in patients with severe COPD, with
shortness of breath being the most frequently reported
symptom, followed by sputum production and cough
[3]. Overall, the proportion of patients who reported
worst symptoms in the morning (37%) was higher than
the proportion reporting more pronounced symptoms at
any other times of the day (Figure 1). This difference
was even more pronounced in patients with severe
COPD (46%; p < 0.001; Figure 1). Night was the second
most bothersome time with respect to symptoms as
reported by 25% of all patients and 34% of patients with




























Figure 1 Time when COPD symptoms are worse than usual as report
and difficult to say group; p = 0.006 versus no particular time of the day; †p
Reproduced with permission of Informa Healthcare [3].exists between early morning and night-time symptoms
is not yet known.
The survey also revealed that morning symptoms had
a significant impact on morning routine and negatively
affected patients’ quality of life. Indeed, 74% of all pa-
tients and 96% of severe patients reported that they took
longer to complete their morning routine than they used
to before having COPD. Thirty-seven percent of all pa-
tients with COPD and 73% of patients with severe
COPD reported their problems with morning routine as
bothersome.
Observational studies in large cohorts of patients con-
firmed that all COPD symptoms were most problematic
upon waking [7,13,14]. At this time, the symptoms
reported as particularly bothersome by the highest pro-
portion of patients were sputum production (phlegm),
followed by cough (Figure 2) [7].
In a study by Kim et al., all COPD symptoms were
more frequent and severe in patients with symptoms in
the morning than in those without, with symptom scores
of breathlessness and chest tightness significantly in-
creased in patients experiencing symptoms in the morn-
ing [14]. Interestingly, in this study treatment with a
LAMA was associated with fewer morning symptoms.
In addition, the study by Kessler et al. showed that the
variability of breathlessness during the course of the day
and the week correlated with the severity of this symp-
tom, suggesting that both features are associated with
the degree of respiratory impairment and its impact on
exercise limitation and daily activity [7]. The variability
of breathlessness during the week was also associated
with frequent exacerbations (two or more) in the previ-
ous year, confirming earlier findings linking symptoms
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Figure 2 Patients who had reported experiencing symptoms in
the previous 7 days were asked during what times of the day
the symptoms were most troublesome: a) Breathlessness,
n = 1,769; b) phlegm, n = 1,551; c) cough, n = 1,433; d)
wheezing, n = 1,018; and e) chest tightness, n = 690. © 2002
European Respiratory Society. Reproduced with permission of the
European Respiratory Society [7].
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patients at risk of future exacerbations i.e., belonging to
the so-called frequent exacerbator phenotype [15].
More recently, an analysis investigating the impact of
symptoms in the morning by self-completion question-
naires in a working COPD population receiving an ICS/
LABA fixed-dose combination has further revealed that,
in addition to affecting morning activities, these symp-
toms were associated with an increased risk of exacerba-
tions [8]. Patients with symptoms in the morning had
significantly more exacerbations in the previous 12
months than those without (1.04 versus 0.63; p = 0.005).
Although no causality was established in this study,
these findings suggest that the presence of morning
symptoms could be a marker of globally increased air-
ways instability, which could itself be associated with an
increased risk of acute worsening. Predictably, patients
experiencing symptoms in the morning had a significant
wider range of symptoms (3.2 versus 1.6; p < 0.0001) and
were 1.73 times more likely to use their rescue inhaler in
the previous 4 weeks than those without (p = 0.038) in
order to achieve better symptom control [6]. The ana-
lysis also revealed that patients with symptoms in the
morning took significantly more days off work in the
previous 12 months (4.03 versus 2.27; p < 0.01) than
those without. This highlights how symptoms in the
morning also affect the working lives of patients, con-
tributing to aggravate the economic burden associated
with COPD.
In contrast to the growing evidence available on the
effect of morning symptoms on different aspects of pa-
tients’ lives, the impact of night-time symptoms on long-
term patient outcomes in COPD is yet to be established
and deserves further investigation.
PRO questionnaires for the evaluation of morning
symptoms
A regular evaluation of symptoms and their variability
by validated patient-reported outcome (PRO) question-
naires is vital for assessing the impact of COPD, the
effect of pharmacological treatments on morning symp-
toms and developing effective management strategies.
Patient-reported questionnaires traditionally utilized to
assess symptoms and health status in patients with
COPD, including the St George’s Respiratory Question-
naire (SGRQ) and the Baseline and Transition Dyspnea
Roche et al. Respiratory Research 2013, 14:112 Page 4 of 8
http://respiratory-research.com/content/14/1/112Index (TDI), do not specifically address the variability of
COPD symptoms nor measure the impact of symptoms
on important routine morning activities [16]. Significant
efforts have been focused on developing validated PRO
tools that specifically capture symptoms in the morning
and the ability to perform morning activities [17].
The Global Chest Symptoms Questionnaire (GCSQ)
and the Capacity of Daily Living during the Morning
(CDLM) questionnaire were developed based on inter-
views with COPD patients and evaluated in two multi-
center, randomized trials involving a total of 1,100
COPD patients, with regards to their reliability, validity
and responsiveness to therapy [17]. One of the studies
evaluated the effect of once-daily tiotropium versus a
combination of tiotropium plus twice-daily budesonide/
formoterol, while the other one compared the effect of
budesonide/formoterol and fluticasone/salmeterol, both
inhaled twice daily. Symptoms were assessed by the
GSCQ questionnaire whereas morning activities, such as
eating breakfast and getting dressed, were assessed using
the CDLM questionnaire (Appendix). The responses
were recorded in an e-diary. CDLM and GCSQ scores
correlated significantly with symptoms, health-related
quality of life evaluated by the SGRQ and use of rescue
medication (all p < 0.001). In addition, significant im-
provement in CDLM and GCSQ scores occurred in
response to treatment (p < 0.001). Minimal important
differences (MIDs) of 0.2 for the CDLM and 0.15 for the
GCSQ questionnaires were estimated based on the
dataset; these correspond to an SGRQ score MID of 4.
Overall, these questionnaires have been shown to be reli-
able and responsive to treatment effects and could dis-
criminate between patients with different health status
[17]. They hold, therefore, significant potential as assess-
ment tools in COPD.
However, these questionnaires may not fully meet new
US Food and Drug Administration’s requirements for
use in clinical trials to support label claims [18]. In order
to overcome this limitation, the Early Morning Symp-
toms of COPD Instrument (EMSCI), a new PRO tool to
evaluate symptoms in the morning, has recently been
developed [19]. An electronic version of this tool is cur-
rently being tested for use in clinical trials.
Given the prevalence of sleep disturbance associated
with night-time symptoms in patients with COPD, new
specific instruments have also been recently developed
to capture sleep problems [20,21]. A COPD night-time
symptoms questionnaire has been specifically designed
for Phase III studies with the novel LAMA aclidinium
but its robustness and validity for use in clinical trials
have not yet been evaluated [22]. In the study, the
frequency of night-time symptoms (including breathless-
ness, cough, sputum production, and wheezing), the
severity and impact of breathlessness and cough onnight-time activity, and the severity and impact of
breathlessness on early morning activity were recorded
by patients using a sleep diary [22]. More recently, the
COPD and Asthma and Sleep Impact Scale question-
naire has been shown to correlate with the SGRQ
questionnaire and discriminate between patients with
different severities, exacerbation status and overall
health status, suggesting that this tool can help under-
stand the impact of COPD on sleep outcomes [23].Controlling morning symptoms in COPD: pharmacological
therapies
Although a significant number of studies have shown
the effectiveness of pharmacological treatment in de-
creasing symptoms in patients with COPD, only a few
have specifically assessed how these treatments can
control early morning symptoms. Several therapeutic
options can be considered in COPD when approaching
morning symptoms. Better (i.e., more stable) 24-hour
coverage provided by once-daily, ultra-long acting bron-
chodilators is a valuable option for alleviating morning
symptoms. Alternatively, better coverage of night-time
and early morning can be achieved by twice-daily dosing
of long-acting bronchodilators [24-26]. Among long-
acting bronchodilators, it might be hypothesized that
fast-acting agents could be more effective on these
symptoms than those with a relatively slow onset of
action by providing a rapid relief of symptoms after
morning dosing [27]. Finally, the combination of bron-
chodilators with different mechanisms of actions, which
has been shown to offer advantages over bronchodilator
monotherapy in controlling COPD symptoms [28], could
potentially offer benefits to patients in the morning.Fast-acting LABAs: indacaterol and formoterol
Indacaterol is a once-daily LABA with a fast onset of ac-
tion, a peak effect at approximately 2 hours and duration
of bronchodilation lasting 24 hours [29-31]. Indacaterol
has a rapid onset of bronchodilation effect following the
first dose. Several different studies have shown that the
range of improvement in mean FEV1 measured at 5 mi-
nutes post-dose was significantly greater with indacaterol
than placebo [29,30], approximately double the corre-
sponding value for the slow-acting LABA salmeterol
[31], and similar to that for the twice-daily LABA
formoterol [29,32] (Table 1). Indacaterol was superior to
formoterol in improving breathlessness, measured using
the TDI score, and health status assessed using the
SGRQ questionnaire, and reducing rescue medication
use [29]. The once-daily dosing of indacaterol could also
potentially have a compliance-enhancing advantage over
the twice-daily formoterol. Further, with its fast onset
of action, indacaterol could have significant morning

































18 q.d. 45–70 mL Approx. 2 hours
Glycopyrronium
[42]
50 q.d 87 mL Approx. 2 hours
b.i.d = twice daily; FEV1 = forced expiratory volume in 1 second; LABAs =
long-acting β2-agonists; LAMAs = long-acting muscarinic antagonists;
q.d. = once daily.
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strate these hypotheses.
The effect of formoterol in combination with ICS on
COPD symptoms in the morning has been evaluated in
two independent studies. In a randomized, double-blind,
double-dummy, cross-over study, budesonide/formoterol
dosed in the morning demonstrated a more rapid onset
of action than salmeterol/fluticasone, as shown by sig-
nificantly greater improvements in FEV1 at 5 minutes
post-dose (120 mL versus 90 mL; p = 0.09) and 15
minutes post-dose (140 mL versus 100 mL; p < 0.05)
[33]. Accordingly, treatment with budesonide/formoterol
resulted in a statistically significant improvement in
total score on CDLM questionnaire compared with
salmeterol/fluticasone. These advantages are likely to be
related to the fast onset of action of formoterol versus
salmeterol post-dose. Their clinical relevance needs to
be explored further.
New fast-acting LAMAs: aclidinium and glycopyrronium
Aclidinium, a novel twice-daily LAMA, has recently
been approved as a maintenance treatment for COPD.
Phase II and Phase III studies, have shown aclidinium
improved lung function, dyspnea, health status and exer-
cise endurance and was well tolerated in patients with
moderate-to-severe COPD [34-37]. In a direct compari-
son, aclidinium did not display a faster onset of action
on bronchodilation than tiotropium [38]. However, as
aclidinium is administered twice daily, it has been hy-
pothesized that there could be less tail-off effect in the
morning, which could be associated with an increased
overall effect on late night and early morning symptoms.
Indeed, in the study by Fuhr et al. aclidinium resulted inimproved bronchodilation at night versus tiotropium, as
demonstrated by significantly greater improvement from
baseline in FEV1 area under the curve (AUC)12–24 hours,
which translated in significantly improvement in night-
time symptoms [25]. Further studies have shown that
aclidinium twice daily improves symptoms (cough and
breathlessness) in the morning/early morning and dur-
ing night-time [22,37,39]. However, effects on morning
symptoms were not compared to overall effect on symp-
toms, which precludes any conclusion regarding a
“specific” effect on morning symptoms versus other
long-acting bronchodilators. Thus, the positive impact of
twice-daily aclidinium on COPD symptoms at night-
time and in the early morning still needs to be con-
firmed using validated PRO questionnaires.
The once-daily LAMA glycopyrronium has also re-
cently been approved for patients with COPD. Phase II
and III clinical trials have shown that once-daily
glycopyrronium produces rapid and sustained 24-hour
bronchodilation in patients with COPD, and has an
acceptable safety and tolerability profile [40-44]. Glyco-
pyrronium also decreases symptoms (i.e., sputum pro-
duction and dyspnea) and the use of rescue medication,
a marker of symptom control, and frequency of exacer-
bation, and improves health status [40,42]. In the
GLOW3 study, glycopyrronium rapidly improved exer-
cise tolerance by reducing dynamic hyperinflation, as
shown by the significant increase in IC at isotime versus
placebo on Day 1 (treatment difference: 230 mL; p <
0.001) [45].
In Phase III studies, once-daily glycopyrronium taken
in the morning displayed a rapid onset of action on Day
1 which was faster than that of tiotropium [42], and
produced a greater increase in FEV1 at 5 minutes
post-dose (Table 1) and greater peak FEV1 and FEV1
AUC0–4 hours than placebo and tiotropium at Day 1 and
Week 26 [42]. This early bronchodilation following
morning dose, could in turn provide quicker relief from
symptoms in the morning, such as shortness of breath,
which hinder patients’ ability to perform simple morning
activities. However, its effect on symptoms experienced
in the morning has not yet been formally evaluated with
validated questionnaires.
The potential of dual bronchodilation in controlling
morning symptoms
Despite the symptomatic benefits that could be provided
by dual bronchodilation to patients with COPD [28], evi-
dence for its impact on morning symptoms is still
scarce. It can be speculated that combining treatments
from different classes should result in additional efficacy.
Studies with the dual bronchodilator QVA149, a fixed-
dose combination of indacaterol and glycopyrronium,
show improvements in lung function and symptoms
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monocomponents used alone [46]. The effect of QVA
149 on morning symptoms is currently under investiga-
tion in clinical trials [47]. Further, in a 12-week, random-
ized, double-blind study budesonide/formoterol added
to tiotropium was shown to rapidly improve lung func-
tion (mean treatment difference for FEV1 at 5 minutes
post-dose 123 mL; p < 0.001) compared with tiotropium
alone, mainly owing to the fast onset of action of
formoterol [48]. This was associated with significant im-
provements in morning symptoms, including breathless-
ness, as evaluated by the CDLM questionnaire, as well
as increased patients’ ability to perform morning activ-
ities. However, as the study did not include a tiotropium
plus formoterol arm, it is difficult to discern the contri-
bution of pure dual bronchodilation to the overall results
and further studies are warranted. Nevertheless, the re-
sults of the study suggest that a fast-acting component
might be useful to help control morning symptoms in
patients on LABA/ICS treatment.Conclusions
COPD symptoms in the morning are strongly associated
with problems experienced by patients in performing
simple morning activities, resulting in a noticeable im-
pact on patients’ quality of life. These symptoms, which
are particularly pronounced in patients with severe
COPD, often result in work absenteeism therefore con-
tributing to aggravate the already substantial economic
burden imposed by COPD.
In light of this consideration, the development of vali-
dated PRO tools able to capture the experience of pa-
tients with regards to symptoms in the morning
becomes vital for evaluating the impact of this disease
on patients’ lives and establishing effective and compre-
hensive management strategies. A number of available
PRO questionnaires have already been used to assess the
effect of therapeutic interventions on symptoms in the
morning. The CDLM and GCSQ questionnaire have
been utilized in two clinical trials evaluating the effect of
the budesonide/formoterol fixed-dose combination ver-
sus combination therapy with salmeterol/fluticasone or
budesonide/formoterol added to the LAMA tiotropium
versus tiotropium alone. Budesonide/formoterol pro-
vided a better control of symptoms in the morning than
salmeterol/fluticasone, which was associated with a posi-
tive effect on morning activities. Similar results were
obtained with budesonide/formoterol plus tiotropium
compared with tiotropium alone. In both studies, a
rapid improvement of morning lung function, which
was the result of the fast onset of action of formoterol,
was associated with positive outcomes with regards to
symptoms in the morning. This highlights the potentialthat other fast-acting bronchodilators could have in this
context.
The newly approved twice-daily LAMA aclidinium has
been shown to significantly and rapidly improve morn-
ing lung function as well as reduce symptoms at night-
time and in the early morning. As this effect of
aclidinium was assessed by a non-validated question-
naire specifically developed for these studies, whether
the same results will be obtained with validated tools
still remain to be assessed.
The new once-daily LAMA glycopyrronium displays a
faster onset of action and greater early bronchodilation
than tiotropium following morning dosing, and could
have the potential to reduce COPD symptoms in the
morning, enabling patients to cope with morning activ-
ities. Evaluation of its effect on COPD symptoms in the
morning is needed.
Although reliable and responsive, many of the PRO
questionnaires validated in clinical trials so far have been
designed before new regulatory guidelines and could not
be used to support labeling claims. The ongoing collab-
oration between regulatory bodies, academia and the
pharmaceutical industry is driving the development of
standardized instruments able to satisfy regulatory re-
quirement, such as the EMSCI tool. Such tools could be
consistently used to evaluate the success or failure of
therapeutic interventions throughout the drug develop-
ment process, therefore allowing the comparison be-
tween different agents.
In conclusion, we believe that given the importance of
morning symptoms and the existence of validated in-
struments, the impact of morning symptoms should be
evaluated in future clinical trials, particularly focusing
on their relationship with long term outcomes and re-
sponse to treatment effects.
Appendix. Patient-reported outcomes
questionnaire
A. Global Chest Symptoms questionnaire
1. How short of breathe are you feeling right now?
2. How tight does your chest feel right now?B. Capacity of Daily Living during the Morning
questionnaire
1. Did you wash yourself this morning other
then your face?
2. Did you dry yourself with a towel after washing
this morning?
3. Did you get dressed this morning?
4. Did you eat breakfast this morning
5. Did you walk around the home this morning
after taking your medicine?
6. Did you walk around d your home later
this morning?
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ately, very or extremely.
[B] If the patient answered 'Yes, I did it myself ’
(question 1 − 3) or 'Yes, I did' (question 4 − 6)
The question was followed by 'How difficult was it to
complete the activity?' (patient responses: not at all, a lit-
tle, moderately, very or extremely).
Each time was scored on a scale ranging from 0 (so diffi-
cult that the activity could not be carried out by the pa-
tients themselves) to 5 (activity not all difficult to catty out).
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